AR105485A1 - Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo - Google Patents

Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo

Info

Publication number
AR105485A1
AR105485A1 ARP160101975A ARP160101975A AR105485A1 AR 105485 A1 AR105485 A1 AR 105485A1 AR P160101975 A ARP160101975 A AR P160101975A AR P160101975 A ARP160101975 A AR P160101975A AR 105485 A1 AR105485 A1 AR 105485A1
Authority
AR
Argentina
Prior art keywords
cysteine
absent
valine
glutamic acid
arginine
Prior art date
Application number
ARP160101975A
Other languages
English (en)
Inventor
Chang Kwon Se
Youb Jung Sung
Ki Lim Chang
Jin Park Young
Min Lee Jong
Suk Lee Jong
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR105485A1 publication Critical patent/AR105485A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Desarrollo de variantes de glucagón para mejorar los efectos terapéuticos en la hipoglucemia y obesidad. Estas variantes de glucagón presentan solubilidad y estabilidad alta a pH neutro. Reivindicación 1: Una composición farmacéutica para el tratamiento o la prevención de síndromes metabólicos que comprende i) un péptido que comprende la secuencia de aminoácidos de la fórmula general (1), y ii) al menos un compuesto o material que tiene una actividad terapéutica para el síndrome metabólico, X¹-X²-QGTF-X⁷-SD-X¹⁰-S-X¹²-X¹³-X¹⁴-X¹⁵-X¹⁶-X¹⁷-X¹⁸-X¹⁹-X²⁰-X²¹-F-X²³-X²⁴-W-L-X²⁷-X²⁸-X²⁹-X³⁰ (fórmula general (1), SEQ ID Nº: 45) en la que, en la fórmula general (1), X¹ es histidina, desamino-histidil, N-dimetil-histidil, b-hidroxi imidazopripionilo, 4-imidazoacetilo, b-carboxi imidazopropionilo, triptófano o tirosina, o está ausente; X² es ácido a-metil-glutámico, ácido aminoisobutírico (Aib), D-alanina, glicina, Sar(N-metilglicina), serina o D-serina; X⁷ es treonina, valina o cisteína; X¹⁰ es tirosina o cisteína; X¹² es lisina o cisteína; X¹³ es tirosina o cisteína; X¹⁴ es leucina o cisteína; X¹⁵ es ácido aspártico, ácido glutámico o cisteína; X¹⁶ es ácido glutámico, ácido aspártico, serina, ácido a-metil-glutámico, o cisteína, o está ausente; X¹⁷ es ácido aspártico, glutamina, ácido glutámico, lisina, arginina, serina, cisteína o valina, o está ausente; X¹⁸ es alanina, ácido aspártico, ácido glutámico, arginina, valina o cisteína, o está ausente; X¹⁹ es alanina, arginina, serina, valina o cisteína, o está ausente; X²⁰ es lisina, histidina, glutamina, ácido aspártico, lisina, arginina, ácido a-metil-glutámico o cisteína, o está ausente; X²¹ es ácido aspártico, ácido glutámico, leucina; valina o cisteína, o está ausente; X²³ es isoleucina, valina y arginina, o está ausente; X²⁴ es valina, arginina, alanina, cisteína, ácido glutámico, lisina, glutamina, ácido a-metil-glutámico, o leucina, o está ausente; X²⁷ es isoleucina, valina, alanina, lisina, metionina, glutamina, o arginina, o está ausente; X²⁸ es glutamina, lisina, asparagina o arginina o está ausente; X²⁹ es lisina, alanina, glicina, o treonina, o está ausente; y X³⁰ es cisteína, o está ausente; con la condición de que cuando la secuencia de aminoácidos de la fórmula general (1) es idéntica a la SEQ ID Nº 1, se excluye.
ARP160101975A 2015-06-30 2016-06-29 Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo AR105485A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20150093265 2015-06-30

Publications (1)

Publication Number Publication Date
AR105485A1 true AR105485A1 (es) 2017-10-11

Family

ID=57608802

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101975A AR105485A1 (es) 2015-06-30 2016-06-29 Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo

Country Status (32)

Country Link
US (3) US10696725B2 (es)
EP (2) EP4324519A2 (es)
JP (3) JP6882210B2 (es)
KR (2) KR102005456B1 (es)
CN (1) CN108025041A (es)
AR (1) AR105485A1 (es)
AU (2) AU2016287209B2 (es)
BR (1) BR112017028517A2 (es)
CA (1) CA2991107A1 (es)
CL (5) CL2017003402A1 (es)
CO (1) CO2018000303A2 (es)
CR (1) CR20180034A (es)
DK (1) DK3322437T3 (es)
DO (1) DOP2017000318A (es)
EA (1) EA201890058A1 (es)
EC (1) ECSP18003879A (es)
ES (1) ES2973017T3 (es)
FI (1) FI3322437T3 (es)
HK (1) HK1248129A1 (es)
IL (2) IL256619B (es)
MA (2) MA49545B1 (es)
MX (1) MX2017016845A (es)
NZ (1) NZ739250A (es)
PE (2) PE20180449A1 (es)
PH (1) PH12017502393A1 (es)
PL (1) PL3322437T3 (es)
PT (1) PT3322437T (es)
TN (1) TN2017000555A1 (es)
TW (1) TWI713541B (es)
UA (1) UA127445C2 (es)
UY (1) UY36759A (es)
WO (1) WO2017003191A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
PE20171154A1 (es) 2014-12-30 2017-08-16 Hanmi Pharm Ind Co Ltd Derivados de glucagon con estabilidad mejorada
MX2017016845A (es) 2015-06-30 2018-08-01 Hanmi Pharm Ind Co Ltd Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo.
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
CN108699125B (zh) 2015-12-31 2022-10-28 韩美药品株式会社 胰高血糖素/glp-1/gip受体三重激动剂
UA126662C2 (uk) * 2016-06-29 2023-01-11 Ханмі Фарм. Ко., Лтд. Похідна глюкагону, її кон'югат, композиція, яка її містить, та її терапевтичне застосування
WO2018143729A1 (ko) 2017-02-03 2018-08-09 한미약품 주식회사 지속성이 증가된 생리활성 물질의 결합체 및 이의 용도
CN110545852B (zh) 2017-02-07 2023-05-26 韩美药品株式会社 非肽聚合物接头化合物、包含该接头化合物的缀合物及制备该接头化合物和缀合物的方法
WO2019066603A1 (ko) * 2017-09-29 2019-04-04 한미약품 주식회사 효력이 향상된 지속성 단백질 결합체
BR112021000933A2 (pt) * 2018-07-19 2021-04-27 D&D Pharmatech Inc. polipeptídeo, composição farmacêutica, método de preparação dela e método de prevenção ou tratamento de doenças
KR101990075B1 (ko) * 2018-07-19 2019-06-18 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비만 예방 또는 치료용 약학 조성물
WO2020017919A1 (ko) * 2018-07-19 2020-01-23 한미정밀화학주식회사 생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법
KR20200135618A (ko) * 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
US20210338779A1 (en) * 2018-10-04 2021-11-04 Hanmi Pharm. Co., Ltd Therapeutic use of glucagon and combination including the same
CN109239346B (zh) * 2018-10-31 2019-10-11 中国药科大学 一组代谢标志物在代谢综合征早期诊断方面的应用
KR20200078414A (ko) * 2018-12-21 2020-07-01 한미약품 주식회사 인슐린 및 글루카곤을 포함하는 약학 조성물
PL3936142T3 (pl) * 2019-06-28 2024-05-06 Hanmi Pharm. Co., Ltd. Potrójny agonista wykazujący aktywność względem wszystkich pośród receptorów glukagonu, glp-1 oraz gip do leczenia chorób wątroby
JP2022551282A (ja) * 2019-10-04 2022-12-08 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用
CN110845601B (zh) * 2019-10-12 2021-01-19 广东药科大学 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
IL295744A (en) * 2020-02-21 2022-10-01 Spitfire Pharma Llc glp-1r and gcgr agonists, formulations and methods of use
JP2023526551A (ja) 2020-05-22 2023-06-21 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン誘導体の持続型結合体の液状製剤
KR20220009354A (ko) 2020-07-15 2022-01-24 한미약품 주식회사 글루카곤 유도체 또는 이의 결합체의 간질환에 대한 치료적 용도
US20240024426A1 (en) * 2020-08-14 2024-01-25 Hanmi Pharm. Co., Ltd. Hypotensive pharmaceutical composition comprising triple activator having activity for all of glucagon, glp-1, and gip receptors
US20240197834A1 (en) 2021-04-09 2024-06-20 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating chronic renal disease including glucagon derivative
KR20230095666A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 물질 및 이의 용도

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
GB9423277D0 (en) 1994-11-18 1995-01-11 Univ Nottingham Pulsed laser deposition of coatings
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
AU2002317599B2 (en) 2001-07-31 2008-04-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
SI1605897T1 (sl) 2003-03-19 2012-11-30 Lilly Co Eli Polietilen glikol povezane GLP spojine
CN103212084B (zh) * 2003-11-13 2018-07-13 韩美科学株式会社 含有免疫球蛋白fc区作为载体的药物组合物
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
EP2573111A1 (en) 2006-04-20 2013-03-27 Amgen Inc. GLP-1 compounds
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
AU2008205229B2 (en) 2007-01-05 2014-03-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
KR20150116465A (ko) 2007-02-15 2015-10-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
AU2008264750C1 (en) 2007-06-19 2013-01-10 Glytech, Inc. GLP-1 peptide having sugar chain attached thereto
WO2009030738A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
EP2952202B1 (en) 2008-06-17 2017-10-18 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
NZ589847A (en) 2008-06-17 2013-01-25 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
KR20120087875A (ko) * 2009-06-16 2012-08-07 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Ｇｉｐ 수용체-활성 글루카곤 화합물
ME02220B (me) * 2009-07-13 2016-02-20 Zealand Pharma As Analozi acilovanog glukagona
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
EP2512503A4 (en) * 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
EP2525809B1 (en) 2010-01-20 2016-08-03 Zealand Pharma A/S Glucagon-glp1 dual agonists for use in the treatment of cardiac conditions
US20130143798A1 (en) 2010-03-26 2013-06-06 Novo Nordisk A/S Novel glucagon analogues
CA2797089A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
BR112013015389A2 (pt) 2010-12-22 2016-11-22 Univ Indiana Res & Tech Corp análogo de glucagon exibindo atividade de receptor gip
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
JP6284471B2 (ja) 2011-05-18 2018-02-28 メデリス ダイアビーティーズ，エルエルシー インスリン抵抗性のための改善されたペプチドの調合薬
CA2838503C (en) * 2011-06-10 2020-02-18 Hanmi Science Co., Ltd. Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
PH12018501119A1 (en) 2011-06-17 2019-02-04 Hanmi Science Co Ltd A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
EP2729493B1 (en) 2011-07-04 2020-06-10 IP2IPO Innovations Limited Novel compounds and their effects on feeding behaviour
RU2014117678A (ru) 2011-11-17 2015-12-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
US20150005233A1 (en) 2012-02-08 2015-01-01 Seneb Biosciences, Inc. Treatment of hypoglycemia
EP2851429B1 (en) 2012-05-18 2019-07-24 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
EP2864351B1 (en) 2012-06-21 2016-08-10 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
JP6300239B2 (ja) 2012-06-21 2018-03-28 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Ｇｉｐ受容体活性を示すグルカゴンアナローグ
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
EA031852B1 (ru) * 2012-11-06 2019-03-29 Ханми Фарм. Ко., Лтд. Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина
KR102213907B1 (ko) 2012-11-20 2021-02-09 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 약제
WO2014081864A1 (en) 2012-11-20 2014-05-30 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
BR112015014510A2 (pt) 2012-12-21 2017-11-21 Sanofi Sa agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais
KR20160021758A (ko) 2013-04-18 2016-02-26 노보 노르디스크 에이/에스 의학용으로 사용하기 위한 안정하고 연장된 glp-1/글루카곤 수용체 코-아고니스트
EP3033355A1 (en) 2013-08-16 2016-06-22 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
AU2014364589B2 (en) 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
WO2016049190A1 (en) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Incretin-insulin conjugates
US20160137712A1 (en) * 2014-11-13 2016-05-19 AskGene Pharma, Inc. Fusion Proteins With Dual Receptor Agonist Activities
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
PE20171154A1 (es) * 2014-12-30 2017-08-16 Hanmi Pharm Ind Co Ltd Derivados de glucagon con estabilidad mejorada
MX2017016845A (es) 2015-06-30 2018-08-01 Hanmi Pharm Ind Co Ltd Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo.
US20170004368A1 (en) 2015-07-05 2017-01-05 Neteera Technologies Ltd. System and method for biometric detection based on sweat ducts
TW201718629A (zh) * 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
EP3384935A4 (en) 2015-12-02 2019-08-21 Hanmi Pharm. Co., Ltd. PROTEIN COMPLEX UTILIZING A FATTY ACID DERIVATIVE, AND PROCESS FOR PREPARING THE SAME
CN108699125B (zh) 2015-12-31 2022-10-28 韩美药品株式会社 胰高血糖素/glp-1/gip受体三重激动剂

Also Published As

Publication number Publication date
AU2016287209B2 (en) 2023-03-02
CL2023001911A1 (es) 2023-11-17
US10696725B2 (en) 2020-06-30
TW201713681A (zh) 2017-04-16
FI3322437T3 (fi) 2024-02-20
JP2018526333A (ja) 2018-09-13
EP3322437B1 (en) 2024-01-17
MA49545B1 (fr) 2022-03-31
IL256619B (en) 2022-04-01
BR112017028517A2 (pt) 2018-08-28
CR20180034A (es) 2018-04-16
US20180186853A1 (en) 2018-07-05
PE20180449A1 (es) 2018-03-05
CN108025041A (zh) 2018-05-11
DOP2017000318A (es) 2018-04-30
HK1248129A1 (zh) 2018-10-12
CL2023001910A1 (es) 2023-11-17
IL291291A (en) 2022-05-01
CL2017003402A1 (es) 2018-04-20
JP2021102618A (ja) 2021-07-15
US11667688B2 (en) 2023-06-06
CL2023000198A1 (es) 2023-06-30
MA41887A1 (fr) 2018-12-31
WO2017003191A1 (en) 2017-01-05
TN2017000555A1 (en) 2019-04-12
IL291291B2 (en) 2023-06-01
KR102005456B1 (ko) 2019-07-30
NZ739250A (en) 2024-02-23
AU2023201118A1 (en) 2023-04-20
JP6882210B2 (ja) 2021-06-02
MA49545A1 (fr) 2021-09-30
EP3322437A4 (en) 2019-10-09
IL256619A (en) 2018-04-30
KR20170003466A (ko) 2017-01-09
EA201890058A1 (ru) 2018-07-31
MX2017016845A (es) 2018-08-01
ECSP18003879A (es) 2018-03-31
CA2991107A1 (en) 2017-01-05
US11261227B2 (en) 2022-03-01
MA41887B1 (fr) 2020-05-29
TWI713541B (zh) 2020-12-21
JP2023062043A (ja) 2023-05-02
EP3322437A1 (en) 2018-05-23
DK3322437T3 (da) 2024-03-25
PL3322437T3 (pl) 2024-05-20
CO2018000303A2 (es) 2018-07-10
UA127445C2 (uk) 2023-08-30
EP4324519A2 (en) 2024-02-21
PT3322437T (pt) 2024-03-20
UY36759A (es) 2017-01-31
KR102395855B1 (ko) 2022-05-10
CL2023001909A1 (es) 2023-11-17
PH12017502393A1 (en) 2018-06-25
US20220127325A1 (en) 2022-04-28
US20200223897A1 (en) 2020-07-16
KR20190092343A (ko) 2019-08-07
PE20240215A1 (es) 2024-02-16
AU2016287209A1 (en) 2018-02-15
ES2973017T3 (es) 2024-06-18

Similar Documents

Publication Publication Date Title
AR105485A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
AR103322A1 (es) Derivados de glucagón con estabilidad mejorada
PE20190355A1 (es) Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo
AR086866A1 (es) Derivados de oxintomodulina y composicion farmaceutica que los comprende para el tratamiento de la obesidad
AR086969A1 (es) Conjugado que comprende oxontomodulina y un fragmento de inmunoglobulina, y su uso
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
UY37998A (es) Agentes antivirales contra la hepatitis b
EA201992247A1 (ru) Быстрая и контролируемая доставка композиций с восстановленным эффектом антуража
PE20191716A1 (es) Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
CL2016001405A1 (es) A peptide mixture
CY1115918T1 (el) Συνθεσεις βασιζομενες επι διακλαδισμενης αλυσου αμινοξεων για βελτιωση της μυοκαρδιακης κοιλιακης λειτουργιας σε ασθενεις που υποφερουν απο διαβητη
NZ579566A (en) Modified fgf-21 polypeptides and their uses
BR112021023957A2 (pt) Peptídeos
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
AR068020A1 (es) Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico
MX2017006748A (es) Composiciones de aminoácidos para el tratamiento de síntomas de enfermedades.
NZ736652A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
BR112015032556A2 (pt) Proteína matriz (m) modificada de um vírus da estomatite vesicular (vsv); sequência de nucleotídeos que codifica uma proteína matriz modificada de um vírus da estomatite vesicular; vírus da estomatite vesicular recombinante (rvsv); vacina; vacina de combinação de preparação e reforço; kit; peptídeo isolado; sequências de nucleotídeos isoladas; uso da vacina; uso da vacina de combinação de preparação e reforço; método para induzir uma resposta imunológica em um indivíduo
NZ756128A (en) Novel peptides and analogs for use in the treatment of oral mucositis
MY187022A (en) Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy
CA3010982A1 (en) Alpha chain of the high-affinity ige receptor (fceria)
BR112018071215A2 (pt) peptídeo para uso no tratamento, melhora ou prevenção de osteoartrite
AR108969A1 (es) Derivado de glucagón, un conjugado del mismo, y una composición que comprende el mismo, y un uso terapéutico del mismo
CR20180008A (es) Variantes de il-37
RU2013146452A (ru) Инъекционный или инфузионный раствор триазавирина для лечения вирусных инфекций